Compare Sun Pharma with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ALEMBIC LTD - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ALEMBIC LTD SUN PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 500.9 49.7 1,008.1% View Chart
P/BV x 3.1 4.3 72.2% View Chart
Dividend Yield % 0.5 0.2 217.1%  

Financials

 SUN PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
ALEMBIC LTD
Mar-18
SUN PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs67972 942.8%   
Low Rs37534 1,107.4%   
Sales per share (Unadj.) Rs121.14.7 2,577.2%  
Earnings per share (Unadj.) Rs13.46.1 219.2%  
Cash flow per share (Unadj.) Rs20.76.2 331.2%  
Dividends per share (Unadj.) Rs2.750.20 1,375.0%  
Dividend yield (eoy) %0.50.4 138.1%  
Book value per share (Unadj.) Rs172.640.7 424.5%  
Shares outstanding (eoy) m2,399.26267.03 898.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.411.3 38.6%   
Avg P/E ratio x39.48.7 454.2%  
P/CF ratio (eoy) x25.58.5 300.6%  
Price / Book Value ratio x3.11.3 234.5%  
Dividend payout %20.63.3 627.4%   
Avg Mkt Cap Rs m1,264,65014,139 8,944.3%   
No. of employees `00017.5NA-   
Total wages/salary Rs m59,671207 28,770.9%   
Avg. sales/employee Rs Th16,608.1NM-  
Avg. wages/employee Rs Th3,409.6NM-  
Avg. net profit/employee Rs Th1,833.8NM-  
INCOME DATA
Net Sales Rs m290,6591,255 23,156.4%  
Other income Rs m10,255370 2,770.1%   
Total revenues Rs m300,9141,625 18,513.2%   
Gross profit Rs m63,076111 56,774.0%  
Depreciation Rs m17,53338 46,382.3%   
Interest Rs m5,5532 326,617.6%   
Profit before tax Rs m50,246442 11,373.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,00924 25,088.9%   
Profit after tax Rs m32,0931,630 1,969.1%  
Gross profit margin %21.78.9 245.2%  
Effective tax rate %12.05.4 220.6%   
Net profit margin %11.0129.8 8.5%  
BALANCE SHEET DATA
Current assets Rs m310,6921,867 16,640.3%   
Current liabilities Rs m173,396591 29,329.5%   
Net working cap to sales %47.2101.6 46.5%  
Current ratio x1.83.2 56.7%  
Inventory Days Days9994 105.1%  
Debtors Days Days11274 151.7%  
Net fixed assets Rs m232,4771,791 12,981.0%   
Share capital Rs m2,399534 449.2%   
"Free" reserves Rs m411,69110,324 3,987.8%   
Net worth Rs m414,09110,858 3,813.8%   
Long term debt Rs m15,22641 36,956.6%   
Total assets Rs m646,93811,591 5,581.6%  
Interest coverage x10.0260.9 3.9%   
Debt to equity ratio x00 969.0%  
Sales to assets ratio x0.40.1 414.9%   
Return on assets %5.814.1 41.3%  
Return on equity %7.815.0 51.6%  
Return on capital %10.215.2 66.9%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m66,02519 340,337.1%   
Fx outflow Rs m38,610264 14,635.1%   
Net fx Rs m27,415-244 -11,216.4%   
CASH FLOW
From Operations Rs m21,965236 9,314.9%  
From Investments Rs m-6,813-224 3,041.3%  
From Financial Activity Rs m-27,305-27 102,651.1%  
Net Cashflow Rs m-8,442-15 57,037.2%  

Share Holding

Indian Promoters % 63.7 64.0 99.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.2 2,565.0%  
FIIs % 23.0 9.7 237.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 26.1 31.8%  
Shareholders   133,026 54,701 243.2%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  DR. REDDYS LAB  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Healthcare and Metal Stocks Witness Selling(Closing)

After staging a gap-down opening, Indian share markets recovered losses as the session progressed and ended on a flat note.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

This 20 Year Cycle Suggests Gold is Set for an August Rally(Profit Hunter)

Jul 31, 2020

The real reason why gold prices will go up more.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 12, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - PIRAMAL ENTERPRISES COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS